Anesticap Drug Interactions

ANESTICAP 1% MCT/LCT can be used in combination with other medicinal products for anesthesia (pre-medications, volatile anesthetics, analgesics, muscle relaxants, local anesthetics). Severe interactions with these medicinal products have been reported. Some of these centrally acting medicinal products may exhibit a circulatory and respiratory depressive effect, thus leading to increased effects when used together with ANESTICAP 1% MCT/LCT.
Lower doses may be required when general anesthesia is carried out in conjunction with regional anesthesia.
Concomitant use of benzodiazepines, parasympatholytic agents or inhalational anesthetics has been reported to prolong the anesthesia and to reduce the respiratory rate.
After additional premedication with opioids, the sedative effects of Propofol may be intensified and prolonged, and there may be a higher incidence and longer duration of apnea.
It should be taken into consideration that concomitant use of Propofol and medicinal products for pre-medication, inhalation agents, or analgesic agents may potentiate anesthesia and cardiovascular side effects.
Concomitant use of central nervous system depressants (e.g., alcohol, general anesthetics, narcotic analgesics) will result in intensification of their sedative effects. When ANESTICAP 1% MCT/LCT is combined with centrally depressant agents administered parenterally, severe respiratory and cardiovascular depression may occur.
After administration of fentanyl, the blood level of Propofol may be temporarily increased with an increase in the rate of apnea.
Bradycardia and cardiac arrest may occur after treatment with suxamethonium or neostigmin.
Leucoencephalopathy has been reported with administration of lipid emulsions such as Propofol in patients receiving cyclosporine.
As some of these drugs are reported to act hypotension or to impair respiration, concomitant use of ANESTICAP 1% MCT/LCT may intensify these effects.